JPWO2021195017A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021195017A5
JPWO2021195017A5 JP2022548517A JP2022548517A JPWO2021195017A5 JP WO2021195017 A5 JPWO2021195017 A5 JP WO2021195017A5 JP 2022548517 A JP2022548517 A JP 2022548517A JP 2022548517 A JP2022548517 A JP 2022548517A JP WO2021195017 A5 JPWO2021195017 A5 JP WO2021195017A5
Authority
JP
Japan
Prior art keywords
vapor
iodine
composition
aqueous solution
article
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022548517A
Other languages
Japanese (ja)
Other versions
JP2023520289A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/023574 external-priority patent/WO2021195017A1/en
Publication of JP2023520289A publication Critical patent/JP2023520289A/en
Publication of JPWO2021195017A5 publication Critical patent/JPWO2021195017A5/ja
Pending legal-status Critical Current

Links

Claims (21)

呼吸器病原体に感染した対象の気道に投与するための蒸気を含む組成物であって、ここで、
(a)前記蒸気は、pHが7.0~10.0の水溶液を、摂氏35~110度(°C)の温度まで加温することによって生成され、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含み、
(b)前記投与は、1日当たり24時間以下であり、
(c)前記患者の気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、組成物。
1. A composition comprising a vapor for administration to the respiratory tract of a subject infected with a respiratory pathogen, comprising:
(a) the vapor is generated by heating an aqueous solution having a pH of 7.0 to 10.0 to a temperature of 35 to 110 degrees Celsius (°C), the aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5 to 10 ppm;
(b) said administration is for 24 hours or less per day ;
(c) a composition wherein the total iodine delivered to the patient's airway does not exceed 16 mg/kg of body weight per day .
呼吸器病原体に感染した対象を処置するためのシステムであって、
pHが7.0~10.0の水溶液が入れられた容器であって、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含む、容器と、
前記容器の中の前記水溶液を摂氏35~110度(°C)の温度まで加温し、これによって蒸気を生成するように構成された加熱要素と、
前記蒸気が呼吸器病原体に感染した対象の気道に到達するように前記蒸気を供給するために構成された人工呼吸器と、を含み、
ここで、前記人工呼吸器は、1日当たり24時間以下、前記蒸気を投与するために構成され、前記気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、システム。
1. A system for treating a subject infected with a respiratory pathogen, comprising:
a container containing an aqueous solution having a pH of 7.0 to 10.0, the aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5 to 10 ppm;
a heating element configured to heat the aqueous solution in the container to a temperature between 35 and 110 degrees Celsius (°C), thereby generating steam;
a ventilator configured to deliver the vapor such that the vapor reaches the airways of a subject infected with a respiratory pathogen;
wherein the ventilator is configured to administer the vapor for no more than 24 hours per day, and wherein the total iodine delivered to the airways does not exceed 16 mg/kg body weight per day.
元素状ヨウ素とヨウ素放出性イオン化合物を含む一定量の投与量パックであって、(a)前記投与量パックをpHが7.0~10.0、かつ総ヨウ素量0.5~10ppmの水溶液に導入すること、(b)前記水溶液を摂氏35~110度(°C)の温度まで加温し、それによって、蒸気を生成すること、(c)前記蒸気を呼吸器病原体に感染した対象の気道に投与することであって、ここで、前記投与が1日当たり24時間以下の投与であり、前記気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、投与することを行うための指示書に伴う、一定量の投与量パック。 1. A dose pack comprising elemental iodine and an iodine-releasing ionic compound, the dose pack being accompanied by instructions for: (a) introducing the dose pack into an aqueous solution having a pH of 7.0-10.0 and a total iodine content of 0.5-10 ppm; (b) warming the aqueous solution to a temperature of 35-110 degrees Celsius (°C), thereby producing a vapor; and (c) administering the vapor to the respiratory tract of a subject infected with a respiratory pathogen, wherein the administration is for no more than 24 hours per day, and wherein the total iodine delivered to the respiratory tract does not exceed 16 mg/kg body weight per day. 製造品であって、請求項2に記載のシステムと、呼吸器病原体に感染した対象の気道に蒸気を投与することにおいて前記システムを使用するための指示書と、を含む、製造品。 An article of manufacture comprising the system of claim 2 and instructions for using the system in administering vapor to the airways of a subject infected with a respiratory pathogen. 前記ヨウ素は前記対象の下気道に供給される、請求項1に記載の組成物。 2. The composition of claim 1 , wherein the iodine is delivered to the lower respiratory tract of the subject . 前記呼吸器病原体は、ウイルス、細菌、真菌類およびミコバクテリアからなる群から選択される、請求項1に記載の組成物。 2. The composition of claim 1 , wherein the respiratory pathogen is selected from the group consisting of viruses, bacteria, fungi and mycobacteria. 前記呼吸器病原体はウイルスである、請求項1に記載の組成物。 The composition of claim 1 , wherein the respiratory pathogen is a virus. 前記呼吸器病原体はCOVID-19である、請求項に記載の組成物。 2. The composition of claim 1 , wherein the respiratory pathogen is COVID-19. 前記ヨウ素放出性イオン化合物は、ヨウ化カリウムまたはポビドンヨウ素である、請求項1~8のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 8, wherein the iodine releasing ionic compound is potassium iodide or povidone iodine. 前記蒸気は、ACE阻害剤、ビタミンD、ヒドロキシクロロキン、亜鉛、コルチコステロイドと抗凝固剤から選択される薬剤、マウスウォッシュ、イベルメクチン、あるいは前記対象の細胞において細胞内pHまたはリソソームpHを増大させる薬物と同時に投与される、請求項1~9のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 9, wherein the vapor is administered simultaneously with an ACE inhibitor, vitamin D, hydroxychloroquine, zinc, a drug selected from a corticosteroid and an anticoagulant, a mouthwash, ivermectin, or a drug that increases intracellular or lysosomal pH in the subject's cells. 前記蒸気および前記対象は、密閉空間内に配置される、請求項1~10のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 10, wherein the vapor and the target are disposed in an enclosed space. 前記蒸気は、呼吸チューブ内に配置される、請求項1~11のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 11, wherein the vapor is disposed in a respiratory tube. 前記蒸気は、呼吸器系フェイスマスク内に配置される、請求項1~11のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 11, wherein the vapor is disposed within a respiratory face mask. 前記蒸気は、鼻プロング内に配置される、請求項1~11のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 to 11, wherein the vapor is disposed within nasal prongs. 前記蒸気は、人工呼吸器内に配置される、請求項1または3~14のいずれか1つに記載の組成物、システム、一定量の投与量パック、または製造品。 The composition, system, metered dose pack, or article of manufacture of any one of claims 1 or 3-14, wherein the vapor is disposed within a ventilator. 前記人工呼吸器は、前記水溶液を含む溶液容器と、前記水溶液の蒸発を促進する加熱要素と動作可能に連結されている、請求項2に記載のシステム。 3. The system of claim 2 , wherein the ventilator is operably coupled to a solution container containing the aqueous solution and a heating element to facilitate evaporation of the aqueous solution. 前記人工呼吸器の圧力および頻度は、前記対象の深呼吸を可能にするように構成される、請求項2に記載の生成器 The generator of claim 2 , wherein the ventilator pressure and frequency are configured to enable the subject to take deep breaths. 前記人工呼吸器はヨウ素の自動補充システムを含む、請求項2に記載の生成器 3. The generator of claim 2 , wherein the ventilator includes an automatic iodine replenishment system. 前記人工呼吸器はアルカリの自動補充システムをさらに含む、請求項に記載の生成器 3. The generator of claim 2 , wherein the ventilator further comprises an automatic alkali replenishment system. 前記人工呼吸器はアルカリの自動補充システムを含む、請求項2に記載の生成器 3. The generator of claim 2 , wherein the ventilator includes an automatic alkali replenishment system. 蒸気を生成する方法であって、前記方法は、1. A method for generating steam, the method comprising:
(a)pHが7.0~10.0の水溶液を、摂氏35~110度(°C)の温度まで加温し、これによって蒸気を生成する工程であって、前記水溶液は、ヨウ素放出性イオン化合物と元素状ヨウ素を総ヨウ素量0.5~10ppmで含む、工程と、(a) heating an aqueous solution having a pH of 7.0-10.0 to a temperature of 35-110 degrees Celsius (°C), thereby producing steam, said aqueous solution comprising an iodine releasing ionic compound and elemental iodine in a total iodine content of 0.5-10 ppm;
(b)前記蒸気を前記対象の気道に1日当たり24時間以下投与する工程であって、ここで、前記気道に送達される総ヨウ素が、1日当たり16mg/kg体重を超えない、工程と(b) administering the vapor to the subject's airway for no more than 24 hours per day, wherein the total iodine delivered to the airway does not exceed 16 mg/kg body weight per day;
を含む、方法。A method comprising:
JP2022548517A 2020-03-23 2021-03-23 Iodinated compounds for treating respiratory pathogens Pending JP2023520289A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062993085P 2020-03-23 2020-03-23
US62/993,085 2020-03-23
US202063026122P 2020-05-17 2020-05-17
US63/026,122 2020-05-17
PCT/US2021/023574 WO2021195017A1 (en) 2020-03-23 2021-03-23 Iodine compounds for treating respiratory pathogens

Publications (2)

Publication Number Publication Date
JP2023520289A JP2023520289A (en) 2023-05-17
JPWO2021195017A5 true JPWO2021195017A5 (en) 2024-04-04

Family

ID=76584294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022548517A Pending JP2023520289A (en) 2020-03-23 2021-03-23 Iodinated compounds for treating respiratory pathogens

Country Status (8)

Country Link
US (1) US20230013142A1 (en)
EP (1) EP4125814A1 (en)
JP (1) JP2023520289A (en)
CN (1) CN115551477A (en)
CA (1) CA3169607A1 (en)
IL (1) IL275909B (en)
MX (1) MX2022010938A (en)
WO (1) WO2021195017A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023118979A1 (en) * 2021-12-22 2023-06-29 Novo Integrated Sciences Inc. System and method for antibody activators in an aqueous iodine solution

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5038769A (en) * 1983-06-29 1991-08-13 Krauser Robert S Method and apparatus for treating ailments
US8303994B2 (en) * 2006-06-22 2012-11-06 Jack Howard Kessler Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells
WO2019009630A1 (en) * 2017-07-04 2019-01-10 김대황 Solid composition comprising iodine agent and sodium chloride having improved water solubility, and antiviral and antimicrobial composition for eye, oral cavity, nasal cavity or inhalation containing aqueous solution thereof

Similar Documents

Publication Publication Date Title
US6651655B1 (en) Inhaled vaccines
US6616914B2 (en) Method for pulmonary and oral delivery of pharmaceuticals
US20080078382A1 (en) Methods and Systems of Delivering Medication Via Inhalation
EP1902742A1 (en) Methods and systems of delivering medication via inhalation
CN101553210A (en) Methods and systems of delivering medication via inhalation
EA022840B1 (en) Pharmaceutical composition, kit, use thereof and method for prophylactics and treatment of a symptom, condition or disease associated with infection by an influenza virus
CN105250245A (en) Atomized inhalant for treating respiratory system diseases
CA3180854A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
Levin et al. Status asthmaticus and pancuronium bromide
JP2022019937A (en) Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals
US20230013142A1 (en) Iodine compounds for treating respiratory pathogens
JPWO2021195017A5 (en)
JP6628449B1 (en) Composition for controlling or reducing obstructive airway disease
WO1999001138A1 (en) A pharmaceutical formulation of uridine triphosphate suitable for administration in a small volume
US11278688B2 (en) Inhaling device for heavy metal salts and a method of use thereof for medical treatment
US20130123364A1 (en) N6-(1-iminoethyl)-l-lysine for regeneration of alveoli in lungs
CA3169607C (en) Iodine compounds for treating respiratory pathogens
Fong et al. Inhalation devices for asthma. Choosing the right one could make all the difference.
Almukhambetova et al. Nebulising therapy of bronchial asthma attacks
AU2020444401A1 (en) Pharmaceutical composition of chlorine for treatment of respiratory viral infection
Matthys Nebulizer possibilities and limitations
TW505517B (en) Novel pharmaceutical compositions of uridine triphosphate
WO2023083850A1 (en) Medicament for inhalation or breathing, and inhaler or breathing device comprising same
Li et al. 11 Inhalation Therapy in the Intensive Care Unit
RU2143264C1 (en) Method of treatment of patients with tracheitis